Artificial Intelligence in Cardio-Oncology and Cardiovascular Health

Dear Colleagues,

The convergence of artificial intelligence (AI) and bioengineering has ushered in a new era in the management and treatment of cardiovascular diseases and cancer, particularly in the emerging field of cardio-oncology. As cancer patients often experience cardiovascular complications due to the direct effects of malignancies and their treatments, the integration of AI in cardio-oncology provides an unprecedented opportunity to enhance patient outcomes. AI technologies, including machine learning and deep learning, facilitate the analysis of vast datasets from various sources, enabling researchers and clinicians to identify patterns, predict outcomes, and tailor therapies in a more personalized manner.

AI-driven approaches can significantly enhance the detection, diagnosis, and management of cardiovascular issues in cancer patients. For instance, predictive algorithms can analyze electronic health records (EHRs), imaging data, and genomic information to identify patients at risk of treatment-related cardiotoxicity. Moreover, AI models can assist in the real-time monitoring of cardiovascular status, empowering healthcare providers to intervene early and mitigate serious complications. In this context, AI not only provides the tools for predictive analytics but also enhances the decision-making processes in clinical practice.

The intersection of AI and cardiovascular health extends beyond oncology. The growing prevalence of cardiovascular diseases necessitates innovative solutions for prevention, diagnosis, and management. AI can optimize the design of interventions, improve patient engagement through wearable technology, and enhance adherence to treatment regimens.

This Special Issue aims to collect original research articles, reviews, and case studies that highlight the latest advancements, applications, and challenges of AI within the realms of cardio-oncology and cardiovascular health. By bringing together experts from various disciplines, we aspire to foster a comprehensive dialogue on the future of AI in revolutionizing care for patients with cardiovascular conditions and malignancies.

Dr. Sherry Ann Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• artificial intelligence
• cardio-oncology
• cardiovascular health
• machine learning
• personalized medicine
• cardiovascular toxicity